SMO and pancreatic neoplasm: These observations are in line with data from Steg and colleagues [33] and Wu et al. [34], reporting similar results after SMO inhibition with cyclopamine in human pancreatic cancer cells, or with vismodegib in colon cancer cells, respectively.